Video

Dr. Emily Ko on the Role of Surgery in Endometrial Cancer

Author(s):

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses the role of surgery in endometrial cancer and the candidacy of patients for the procedure.

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses the role of surgery in endometrial cancer and the candidacy of patients for the procedure. Unlike other cancer types, Ko says surgery is an upfront treatment for the patients with endometrial cancer. She adds that while surgery is common and normally the best treatment, patient risk factors such as current health and comorbidities must be taken into account prior to a decision being made.

Ko says surgery is the best option due to endometrial cancers normally being confined to the uterus, and being able to rid the patients of their disease upfront generally portends a positive diagnosis. She adds that some forms of endometrial cancer will present early on with metastases, at which point chemotherapy treatment may be a better option.

<<<

View more from the 2016 SGO Annual Meeting

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.